Shares of ChromaDex (NASDAQ:CDXC) fell in after-market buying and selling after the corporate reported This fall outcomes.
Earnings per share have been up 9.09% over the previous yr to ($0.10), which missed the estimate of ($0.09).
Income of $15,445,000 rose by 18.00% yr over yr, which beat the estimate of $15,360,000.
ChromaDex Sees FY21 Gross sales Progress ‘Regular’ In Ecommerce Unit, Gross Margin Enchancment To Be Barely Higher Than 60%
Convention Name Particulars
Date: Mar 10, 2021
Time: 04:30 PM
ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fwww.google.com%2F&eventid=2947506&sessionid=1&key=BA28949A5DD50002B91BA32E315B1CC9®Tag=&V2=false&sourcepage=register
Firm’s 52-week excessive was at $23.66
Firm’s 52-week low was at $2.50
Worth motion over final quarter: Up 127.37%
ChromaDex Corp is a bioscience firm devoted to wholesome getting older. The ChromaDex group is engaged in analysis on nicotinamide adenine dinucleotide (NAD+), ranges of which decline with age. The corporate is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized because the flagship ingredient Niagen. Nicotinamide riboside and different NAD+ precursors are protected by ChromaDex’s patent portfolio. It delivers Niagen as the only lively ingredient in its client product particularly, Tru Niagen which is obtainable on Tru Niagen’s web site and thru partnerships with retailers and distributors.